SLC5A2 and CFTR-related metabolic syndrome/CF screen positive, inconclusive diagnosis: Additionally, combination regimens pairing incretins with SGLT2 inhibitors, lipid-lowering agents, or anti-inflammatory compounds hold promise for synergistic management of CRMS.